Redcare Pharmacy 관리

Mr. Olaf Heinrich is Chief Executive Officer and Member of the Managing Board at Redcare Pharmacy NV since August 01, 2023. Mr. Heinrich served as Member of the Management Board of “DocMorris” since 2008 u...

리더십 팀

이름	위치	테뉴어	보상	소유권
Olaf Heinrich	CEO & Member of the Managing Board	1.3yrs	€569.15k	데이터 없음
Stephan Weber	Co-Founder & Advisor	less than a year	€880.76k	데이터 없음
Marc Fischer	Co-Founder & Advisor	less than a year	€880.76k	0.60% € 17.8m
Jasper F. Eenhorst	CFO & Member of Management Board	4.8yrs	€1.07m	0.013% € 397.6k
Theresa Holler	COO & Member of the Managing Board	8.8yrs	€886.24k	0.76% € 22.3m
Dirk Bruse	Chief Commercial Officer & Member of Management Board	less than a year	데이터 없음	0.0094% € 277.4k
Lode Fastré	Chief Information Officer & Member of Management Board	less than a year	데이터 없음	데이터 없음
Monica Ambrosi	Associate Director of Investor Relations	no data	데이터 없음	데이터 없음
Patrick Schneider	Chief Sales Officer	no data	데이터 없음	데이터 없음
Beate Krosch	Director of Human Resources	no data	데이터 없음	데이터 없음
Nana Lohmanns	Chief E-Health Officer	no data	데이터 없음	데이터 없음
Jens Wolfgarten	Chief Product Officer - Retail	no data	데이터 없음	데이터 없음

0.8yrs

평균 재임 기간

51yo

평균 연령

경험이 풍부한 관리: RDC 의 관리팀은 경험 (평균 재직 기간 0.8 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Jaska de Bakker	Independent Member of Supervisory Board	2.6yrs	€52.00k	데이터 없음
Jerome Cochet	Independent Member of Supervisory Board	8.2yrs	€49.00k	데이터 없음
Bjorn Soder	Independent Chairman of the Supervisory Board	8.2yrs	€80.00k	데이터 없음
Frank Kohler	Independent Deputy Chairman of Supervisory Board	8.8yrs	€60.00k	1.6% € 47.1m
Henriette Peucker	Independent Member of Supervisory Board	3.6yrs	€49.00k	데이터 없음

8.2yrs

평균 재임 기간

54yo

평균 연령

경험이 풍부한 이사회: RDC 의 이사회는 경험(평균 재직 기간 8.2 년)으로 간주됩니다.

Redcare Pharmacy 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

CFO & Member of Management Board exercised options and sold €622k worth of stock

Redcare Pharmacy NV Announces Management Departures

Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024

CFO & Member of Management Board recently sold €1.0m worth of stock

Co-Founder recently sold €454k worth of stock

COO & Member of the Managing Board recently sold €331k worth of stock

Recent updates

CFO & Member of Management Board exercised options and sold €622k worth of stock

Here's Why Redcare Pharmacy (ETR:RDC) Can Afford Some Debt

Third quarter 2024 earnings released

Consensus EPS estimates fall by 33%

Redcare Pharmacy NV Revises Sales Guidance for the Full Year 2024

Second quarter 2024 earnings released

Redcare Pharmacy NV (XTRA:RDC) acquired MediService AG.

Forecast to breakeven in 2025

First quarter 2024 earnings released

Is There Now An Opportunity In Redcare Pharmacy NV (ETR:RDC)?

Are Investors Undervaluing Redcare Pharmacy NV (ETR:RDC) By 26%?

Investors Interested In Redcare Pharmacy NV's (ETR:RDC) Revenues

Redcare Pharmacy NV Announces Management Departures

New minor risk - Shareholder dilution

Forecast breakeven date moved forward to 2024

Redcare Pharmacy NV to Report Q3, 2024 Results on Nov 05, 2024

Full year 2023 earnings: EPS exceeds analyst expectations

Redcare Pharmacy NV, Annual General Meeting, Apr 17, 2024

Redcare Pharmacy (ETR:RDC) Is Carrying A Fair Bit Of Debt

Price target increased by 7.6% to €142

Consensus EPS estimates upgraded to €0.86 loss

Why Investors Shouldn't Be Surprised By Redcare Pharmacy NV's (ETR:RDC) P/S

Is There An Opportunity With Redcare Pharmacy NV's (ETR:RDC) 48% Undervaluation?

Forecast breakeven date moved forward to 2024

Consensus estimates of losses per share improve by 24%

Third quarter 2023 earnings released

Is Redcare Pharmacy (ETR:RDC) Using Too Much Debt?

Consensus EPS estimates upgraded to €1.43 loss

CFO & Member of Management Board recently sold €1.0m worth of stock

Consensus estimates of losses per share improve by 20%

New minor risk - Share price stability

Now 21% undervalued

Why Redcare Pharmacy NV (ETR:RDC) Could Be Worth Watching

Why We're Not Concerned About Redcare Pharmacy NV's (ETR:RDC) Share Price

Consensus EPS estimates fall by 16%

New minor risk - Profitability

Consensus EPS estimates upgraded to €1.64 loss

Price target increased by 8.1% to €101

Broker Revenue Forecasts For Shop Apotheke Europe N.V. (ETR:SAE) Are Surging Higher

Consensus revenue estimates increase by 19%

Price target increased by 7.5% to €99.08

Consensus EPS estimates fall by 15%

Consensus EPS estimates fall by 15%, revenue upgraded

Co-Founder recently sold €454k worth of stock

Here's Why Shop Apotheke Europe (ETR:SAE) Can Afford Some Debt

First quarter 2023 earnings released

Price target increased by 7.5% to €90.00

COO & Member of the Managing Board recently sold €331k worth of stock

Consensus EPS estimates upgraded to €2.36 loss, revenue downgraded

Full year 2022 earnings: EPS misses analyst expectations

No longer forecast to breakeven

COO & Member of the Managing Board recently sold €149k worth of stock

We Think Shop Apotheke Europe (ETR:SAE) Has A Fair Chunk Of Debt

Now 22% undervalued

Forecast to breakeven in 2025

Chairman of the Managing Board & CEO recently bought €85k worth of stock

Shop Apotheke Europe N.V. to Report Fiscal Year 2022 Results on Mar 07, 2023

Price target decreased to €91.64

Third quarter 2022 earnings released

Price target decreased to €98.79

Is Shop Apotheke Europe (ETR:SAE) Using Too Much Debt?

Co-Founder recently sold €972k worth of stock

Consensus forecasts updated

No longer forecast to breakeven

Second quarter 2022 earnings released

Shop Apotheke Europe N.V. Re-Confirms Earnings Guidance for 2022

COO & Member of the Managing Board recently sold €1.5m worth of stock

Co-Founder recently sold €953k worth of stock

Is Shop Apotheke Europe (ETR:SAE) Weighed On By Its Debt Load?